Questionnaire survey of the efficacy of emollients for adult patients with atopic dermatitis

Emollients are useful and important treatment adjuncts for patients with atopic dermatitis (AD). Heparinoid mucopolysaccharide creams or lotions are emulsion ointments for moisturizing the skin. The objective of this study was to investigate the view among adult AD patients regarding the effectiveness of emollients. We developed a questionnaire at our University Hospital to characterize how patients with AD viewed the efficacy of emollients. Patients were asked to participate prior to treatment and the questionnaire was given within 1 month of treatment. The severity of AD was graded as mild, moderate, severe or very severe. The severity scoring was performed only when the participants answered the questionnaire. Of the 110 enrolled AD patients, 103 returned the completed questionnaires. Ninety‐eight patients (95.1%) used heparinoid mucopolysaccharide creams or lotions. There was a strong correlation between their view of the efficacy of the emollient and the condition of dry skin, pruritus and eczematous skin. There was a significant correlation between AD severity and the perceived efficacy of the emollient for dry skin, pruritus and eczematous skin. There was a greater sense of efficacy among patients with milder AD than in more severe AD cases. Patients who felt sufficient efficacy of the emollient for pruritus were significantly older than those who felt there was no efficacy. In addition, the age of onset of AD was significantly higher among those who felt sufficient efficacy for pruritus compared to those who felt little efficacy. We speculate that the efficacy of emollients could be demonstrated in the treatment of milder AD, but may only have partial efficacy in more severe cases. Emollient therapy might have lower efficacy for pruritus among younger or earlier onset AD patients.

[1]  M. Lodén,et al.  Treatment with a barrier‐strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  M. Ohtsuki,et al.  Guidelines for management of atopic dermatitis , 2009, The Journal of dermatology.

[3]  W. McLean,et al.  Eczema genetics: current state of knowledge and future goals. , 2009, The Journal of investigative dermatology.

[4]  N. Klopp,et al.  Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. , 2006, The Journal of allergy and clinical immunology.

[5]  Colin N A Palmer,et al.  Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis , 2006, Nature Genetics.

[6]  R. Damstra,et al.  Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study , 2003, BMJ : British Medical Journal.

[7]  J. Hanifin,et al.  Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients , 2002, The British journal of dermatology.

[8]  M. Pecegueiro,et al.  Contact dermatitis to Hirudoid® cream , 1987, Contact dermatitis.

[9]  H. Kerckhoffs,et al.  Contact allergy to a reaction product in Hirudoid® cream: an example of compound allergy , 1987, The British journal of dermatology.

[10]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.

[11]  J. Brunkwall,et al.  Treatment of superficial thrombophlebitis. A comparative trial between placebo, Hirudoid cream and piroxicam gel. , 1990, Annales chirurgiae et gynaecologiae.